Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRT Followed by Durvalumab and Tremelimumab for HCC With PVT
NCT07122089Phase 2Recruiting
- Sponsor
- Centre Eugène Marquis
- Start
- Feb 2026
- Primary completion
- Jan 2030
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in hepatocellular carcinoma (HCC), sponsored by Centre Eugène Marquis. Started Feb 2026; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07122089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122089.